Health Canada has approved the use of Radiosse, a bio -stimulatory dermal filling, for the treatment of moderate wrinkles in the Decolleté area. The regulatory milestone expands the uses approved in Canada beyond the face and hands.
Radiosse, developed by Merz Aesthetics, is designed to stimulate the natural production of collagen and body elastin. The new indication follows a multicentric clinical trial that demonstrated a significant improvement in the appearance of moduction decleta wrinkles.
“Despite being one of the most visible areas of our bodies, the Decolleté area is overlooked when it comes to aesthetics,” says Dr. Samantha Kerr, scientific director of Merz Aesthetics, in a statement. “Radiosse presents a unique solution to improve decision wrinkles and provides our clients with their patients a non -surgical and effective option to address the skin of aging decision.”
Dusan Sajic, MD, PHD, a Canadian medical and cosmetic dermatologist, described the chest area as “notoriously difficult to treat” due to its thin skin, high exposure to the sun and reduced activity of the Sebaceous gland. Sajic adds that the bio -stimulating effects of the radioesse, which “work by triggering collagen, elastin and renewal of microvulature”, overcoming a clinical method to rejuvenate the decolleté.
Radiosse has been available worldwide since 2005 and celebrates its twentieth year in the market. More than 15 million syringes have been sold worldwide, according to Merz. In Canada, the new approval allows the flexibility of the treatment, including a dilution of 1: 2 with a sterile saline solution to adapt the procedures based on the individual needs of the patients.
“This new indication for Radios to treat the Decolleté area marks a significant milestone for the aesthetics market,” says Chris Van Dyk, country manager of Merz Aesthetics Canada, in a statement. “Not only expands the versatility of Radiosse, but also addresses a growing demand for patients with regenerative aesthetic solutions.”